Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Heinz Gisslinger(Medical University of Vienna), Richard Greil(Paracelsus Medical University), Nicole C.C. Them(Austrian Academy of Sciences), Pavla Kadlecová, Dominik Wolf(Universität Innsbruck), Ella Willenbacher(Innsbruck Medical University), Alexander Egle(Paracelsus Medical University), Ernst Schloegl(Hanusch Hospital), Oleh Zagrijtschuk(AOP Orphan (Austria)), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Martin Schalling(Karolinska University Hospital), Christoph Klade(Intercell (Austria)), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Karin Strecker(Donauspital), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Guenther Gastl(Innsbruck Medical University), Róbert Královics(Medical University of Vienna)
Cited by 186
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450